The Center for Biosimilars® recaps the top news for the week of November 12, 2018.
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 12.
Number 5: The Canadian Agency for Drugs and Technologies in Health has released a new report that explores international pricing policies related to biosimilars and the factors that facilitate their use.
Number 4: During its investor call last week, Coherus Biosciences revealed that it will launch its biosimilar pegfilgrastim, Udenyca, at a 33% discount to the reference Neulasta.
Number 3: A newly published systematic review investigated the safety and efficacy of switching between reference and biosimilar infliximab in patients with inflammatory disorders.
Number 2: Given the high cost of biologics that treat pediatric inflammatory bowel disease, biosimilars are emerging as an important cost-saving option that can prevent the premature termination of biologic therapy for financial reasons.
Number 1: Genentech recently filed a motion in a US district court seeking an injunction to block JHL Biotech from making and selling potential biosimilars after former Genentech employees were charged with conspiring to steal trade secrets.
Finally, last week, our e-newsletter asked if requiring manufacturers to disclose their insulin’s list pricing process would help curb costs.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.